血色浪漫

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。    08月26日讯 官方消息，31岁拜仁中场帕利尼亚加盟本菲卡，双方签约至2030年。帕利尼亚的转会费总价为1900万欧，固定转会费为1400万欧元，外加最高500万欧元的浮动条款。【官方公告】31岁的中场若昂·帕利尼亚正式成为本菲卡的新援。这位葡萄牙国脚从拜仁转会而来，签约至2030年6月30日。

二 | 关于买断球员全部所有权的协议金额为1400万欧元，此外根据预设目标的达成情况，最高可追加500万欧元浮动条款。合同中包含一项5000万欧元的解约金条款。帕利尼亚现年31岁，2024年夏窗他以5100万欧转会费从富勒姆加盟拜仁，2024/25赛季他为拜仁出场25次，去年夏窗他被拜仁外租至热刺。目前帕利尼亚的身价为1500万欧元。

Current article:http://mltti.ninyakenhongnian.sbs/list_6iq/asyios1.html

Published on:22:40:14